Why the study?
Do omega-3 fatty acids or icosapent ethyl reduce cardiovascular outcomes in patients with hypertriglyceridemia?
Do omega-3 fatty acids or icosapent ethyl reduce cardiovascular outcomes in patients with hypertriglyceridemia?
Answers are grounded in this paper and cite their sources.
Icosapent ethyl reduces cardiovascular outcomes in high-risk and secondary prevention patients with hypertriglyceridemia, unlike EPA/DHA combinations which showed no benefit in primary prevention.
No abstract yet. The journal hasn't published one we can show.
No takes yet. Share an insight, caveat, or question.
Generoso et al. (2019) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: